EMBARK, STUDY 9001-301


Associated tags: Duchenne muscular dystrophy, Week, Part, NSAA, Biotechnology, Interest, Fever, Pharmaceutical industry, Appetite, Patient, Therapy, Physical medicine and rehabilitation, DMD, Roche, Clinical trial, Disease, Sarepta Therapeutics, Genetics, SAE, Nausea, History, Rehabilitation, Vomiting, UC

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Genetics, Health, Clinical Trials, Sarepta, Șaeș, PIN, UC, Vomiting, Rehabilitation, History, Nausea, SAE, Sarepta Therapeutics, Interest, Disease, Clinical trial, Roche, DMD, Physical medicine and rehabilitation, Therapy, Patient, Appetite, Pharmaceutical industry, Fever, Duchenne

Full results from EMBARK will be shared at future medical meetings and publication will be pursued in a medical journal.

Key Points: 
  • Full results from EMBARK will be shared at future medical meetings and publication will be pursued in a medical journal.
  • “The consistency of the positive effect across all timed function tests and age groups provides evidence of a meaningful treatment effect.
  • On October 30, 2023, at 4:30 p.m. Eastern time, Sarepta will host a conference call and webcast to discuss these results.
  • Sarepta is responsible for regulatory approval and commercialization of ELEVIDYS in the U.S., as well as manufacturing.